EPL (500135) Q4 99/00 earnings summary

Executive summary

• FY1999-2000 delivered strong growth: sales and services rose 34% YoY to Rs. 2,484 million, PBT increased 57% to Rs. 507 million and PAT grew 41% to Rs. 366 million.

• Expansion across China, Egypt, Germany and Nepal advanced alongside new products, pharma-market growth and a focus on shareholder returns.

Financial highlights

• Sales and services reached Rs. 2,483.94 million vs Rs. 1,858.34 million; sales and other income totaled Rs. 2,523.58 million vs Rs. 1,865.52 million.

• PBDIT was Rs. 810.39 million vs Rs. 629.21 million; PBT was Rs. 507.26 million vs Rs. 323.12 million; PAT was Rs. 366.44 million vs Rs. 260.62 million.

• Cash profit was Rs. 659.33 million vs Rs. 543.28 million; exports by FOB value rose to Rs. 195.22 million from Rs. 75.65 million.

Outlook and guidance

• Expected growth with the market; plans emphasized further pharma-segment development, customized products for new segments and stronger returns from overseas operations.

• Target set for overseas units to contribute half of PBT within two years; overseas operations were expected to make a growing contribution to enterprise value.

• Egypt expansion planned to lift annual tube capacity from 18 million to 98 million by mid-2000; China was finalizing a potential three-year order for 300 million tubes.